Artificial tears to treat dry eye syndrome
Abstract
Dry eye syndrome (DES) is caused by insufficient tear discharge, abnormal tear composition, or excessive evaporation of the tear film. It is a source of anxiety and discomfort. Treatment of DES is long-lasting and often unsatisfactory. Various treatment regimens are recommended based on the application of tear-imitating liquids produced by the pharmaceutical industry. The use of products approved for clinical use can however be limited by allergic reactions of some patients. In such cases it is recommended to use artificial autologous serum tears.
In some patients, blood collection is impeded and autologous tears cannot be processed. Other ways of obtaining artificial tears from material of human origin are therefore sought. Allogeneic preparations from blood donors are becoming more common. There is ongoing research into obtaining artificial tears with different techniques and from source material other than serum, namely platelet lysate and umbilical cord blood.
In Poland, there are no legal regulations regarding the preparation of artificial tears. The Institute of Hematology and Transfusion Medicine in Warsaw has been preparing autologous artificial tears from serum for over 40 years. Since 2019, research has explored the possibility of using allogeneic preparations.
Finding optimal treatment options for patients unable to use medicinal products, or for whom such products are ineffective, is a huge challenge worldwide. Efforts should be directed at developing the most uniform preparation methods and quality standards for each type of preparation. The growing number of publications on the subject shows the necessity of satisfying this need.
Keywords: dry eye syndromeautologous eye dropsallogenic eye drops
References
- Wytyczne PTO, PTR, PTHiT dot. zapobiegania i leczenia ciężkiego zapalenia rogówki w przebiegu ZSO. https://pto.com.pl/aktualnosci/wytyczne-pto-ptr-pthit-dot-zapobiegania-i-leczenia-ciezkiego-zapalenia-rogowki-w-przebiegu-zso (June 5, 2020).
- Valencia Castillo SL, Sáez Martín E, García Frade LJ, et al. Autologous serum eye drops improve tear production, both lachrymal flow and stability tests and conjunctival impression cytology with transfer in dry eye disease. Blood Transfus. 2021; 19(1): 45–53.
- Higuchi A. Autologous serum and serum components. Invest Ophthalmol Vis Sci. 2018; 59(14): DES121–DES129.
- Marks DC, Fisher J, Mondy P, et al. Serum eye drop preparation in Australia: current manufacturing practice. Transfus Apher Sci. 2015; 53(1): 92–94.
- von Hofsten J, Egardt M, Zetterberg M. The use of autologous serum for the treatment of ocular surface disease at a Swedish tertiary referral center. Int Med Case Rep J. 2016; 9: 47–54.
- European Committee (Partial Agreement) on Organ Transplantation (CD-P-TO). Guide to the quality and safety of tissues and cells for human application. 4th edition. European Directorate for the Quality of Medicines & HealthCare (EDQM), Strasbourg 2019: 413–415.
- van der Meer PF, Seghatchian J, de Korte D. Autologous and allogeneic serum eye drops. The Dutch perspective. Transfus Apher Sci. 2015; 53(1): 99–100.
- Marks DC, van der Meer PF. Biomedical Excellence for Safer Transfusion (BEST) Collaborative. Serum eye drops: a survey of international production methods. Vox Sang. 2017; 112(4): 310–317.
- Zhang J, Crimmins D, Faed JM, et al. Characteristics of platelet lysate compared to autologous and allogeneic serum eye drops. Transl Vis Sci Technol. 2020; 9(4): 24.
- Versura P, Profazio V, Buzzi M, et al. Efficacy of standardized and quality-controlled cord blood serum eye drop therapy in the healing of severe corneal epithelial damage in dry eye. Cornea. 2013; 32(4): 412–418.
- Versura P, Buzzi M, Giannaccare G, et al. Cord blood serum-based eye drops: the impact of donor haematological and obstetric factors on the variability of epidermal growth factor levels. Blood Transfus. 2014; 12(Suppl 1): s44–s50.
- Anitua E, de la Fuente M, Alcalde I, et al. Development and optimization of freeze-dried eye drops derived from plasma rich in growth factors technology. Transl Vis Sci Technol. 2020; 9(7): 35.
- Antoniewicz-Papis J, Lachert E, Janik K, et al. Autologous artificial tears used for treatment of dry eye syndrome in patients with chronic graft versus host disease. Pol Arch Intern Med. 2017; 127(10): 705–707.
- Laguna PJ, Antoniewicz-Papis J, Szajkowska A, et al. Application of autologous artificial tears in a case of an 8-year-old girl with vernal keratoconjunctivitis (Spring Catarrh). Blood. 2017; 130: 4931.
- Antoniewicz-Papis J, Sacharczuk E, Rosiek A, et al. Pilot studies on the possibility of applying allogenic artificial tears. Vox Sang. 2020; 115(Suppl 1): 183. The 36th International ISBT Congress Virtual Meeting 12–16 December 2020.
